Benitec Biopharma (BNTC) Accounts Payables (2025)
Benitec Biopharma (BNTC) posted Accounts Payables of $1.0 million for Q4 2025, up 405.47% sequentially from $201000.0 in Q2 2025.
Powered by 
Analysis
Benitec Biopharma (BNTC) Accounts Payables (2025) Analysis & Trends
Benitec Biopharma has reported Accounts Payables for 1 years, with the latest figure at $1.0 million in Q4 2025.
- Quarterly Accounts Payables changed N/A year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (changed N/A YoY) and the FY2025 annual result came in at $201000.0, changed N/A from the prior year.
- Accounts Payables grew to $1.0 million in Q4 2025 per BNTC's latest filing, from $201000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.0 million in Q4 2025 and troughed at $201000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Benitec Biopharma | 588.88 Mn | 588.88 Mn | - | 1.02 Mn |